BTIG Affirms Buy Rating for Connect Biopharma Holdings, Keeps $10 Price Target Intact

Written by Emily J. Thompson, Senior Investment Analyst

CNTB0%

Source: Benzinga

Updated: Nov 13 2025

0mins

Source: Benzinga

Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.
Exclusive Content: Subscribers gain access to exclusive stories and insights generated by Benzinga reporters, enhancing their trading strategies.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and strategies for market success.
Market Winning Tools: The platform provides tools and resources designed to help traders win in the markets every day.

Discover Tomorrow's Bullish Stocks Today

Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.

Sign up now to unlock expert insights and stay one step ahead of the market trends.

CNTB

$2.48+Infinity%1D

Analyst Views on CNTB

Wall Street analysts forecast CNTB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNTB is 8.67 USD with a low forecast of 7.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Analyst Rating

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 2.480

Low

7.00

Averages

8.67

High

10.00

Current: 2.480

Low

7.00

Averages

8.67

High

10.00

BTIG

Buy

initiated

$10

2025-10-31

Reason

BTIG

Price Target

$10

AI Analysis

2025-10-31

initiated

Buy

Reason

BTIG initiated coverage of Connect Biopharma with a Buy rating and $10 price target. The firm believes rademikibart is "set up to thrive" in the acute settings of both indications of asthma and chronic obstructive pulmonary disorder, supported by its unusually fast and best-in-class onset of effect, the analyst tells investors.

Northland

Outperform

initiated

$7.50

2025-07-22

Reason

Northland

Price Target

$7.50

2025-07-22

initiated

Outperform

Reason

Northland initiated coverage of Connect Biopharma with an Outperform rating and $7.50 price target.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CNTB

Unlock Now

About CNTB

Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company. The Company is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The Company has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

GET FREE REAL TIME NOTIFICATIONS

Stock Monitor for CNTB?

Get Started Free

FREE STOCK RECOMMENDATIONS DAILY

Stock Bullish Tomorrow

Get Started Free

70% BACKTESTED ACCURACY!

Should I Buy CNTB?

Get Started Free

Top News

BTIG Affirms Buy Rating for Connect Biopharma Holdings, Keeps $10 Price Target Intact

Discover Tomorrow's Bullish Stocks Today

Analyst Views on CNTB

About CNTB

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

iShares Expanded Tech-Software ETF Declines Significantly

Landmark Bancorp LARK Q4 2025 Earnings Transcript

Plus Therapeutics Prices Public Offering, Raising $15 Million

BTIG Affirms Buy Rating for Connect Biopharma Holdings, Keeps $10 Price Target Intact

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch